- Exelixis will receive a milestone payment of $50 million
- Approval based on Cabometyx vs versus sunitinib in CABOSUN trial
- Cabometyx was approved for reimbursement in... read more
Pfizer Inc. (NYSE: PFE) announced on 5/17/18 positive top-line results of a Phase 3 study examining the use of Lyrica (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures... read more
Turnstone Biologics announced on 5/16/18 it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug Application (IND) for MG1-HPV for the treatment of... read more
BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), announced on 5/16/18 that the European Patent Office (EPO) has issued a Decision to Grant a patent claiming the use of BL-8040 with cytarabine, a... read more
EIP Pharma, announced on 5/16/18 the successful completion of a $20.5 million Series B financing. The Series B financing was led by Access Industries. This new round follows a Series A... read more